



Application No.: 09/077817

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Daniel Caput et al.

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

Serial No.: 09/077,817

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service addressed to:


Filed: September 14, 1998

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450

Group Art Unit: 1646

Alexandria, VA 22313-1450

Examiner: Basi, N.


Name

For: Purified Polypeptides Having IL-13 Receptor Activity

3/15/04
Date

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


The Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed November 18, 2003, set a one-month shortened statutory period for response expiring December 18, 2003. The period for response is extended three months to March 18, 2004, pursuant to the Petition for Extension of Time under 37 C.F.R. 1.136(a) submitted herewith. This response is therefore timely filed.

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed November 18, 2003, enclosed is a substitute computer readable form (CRF) copy of the "Sequence Listing". Also enclosed is a substitute paper copy of the sequence listing together with an amendment directing its entry into the specification. The substitute computer readable form (CRF) copy and the substitute paper copy are the same and include no new matter as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed.

Respectfully submitted,

Date: 3/15/04


Paul E. Dupont
Reg. No. 27,438

Address:
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355

Tele: (610) 889-6338
Facsimile: (610) 889-8799